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A B S T R A C T
Background
Bronchiectasis is a chronic respiratory disease characterised by abnormal and irreversible dilatation of the smaller airways and associated
with a mortality rate greater than twice that of the general population. Antibiotics serve as front-line therapy for managing bacterial load,
but their use is weighed against the development of antibiotic resistance. Dual antibiotic therapy has the potential to suppress infection
from multiple strains of bacteria, leading to more successful treatment of exacerbations, reduced symptoms, and improved quality of life.
Further evidence is required on the efficacy of dual antibiotics in terms of management of exacerbations and extent of antibiotic resistance.
Objectives
To evaluate the effects of dual antibiotics in the treatment of adults and children with bronchiectasis.
Search methods
We identified studies from the Cochrane Airways Group Specialised Register (CAGR), which includes the Cochrane Central Register of Con-
trolled Trials (CENTRAL), MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Allied and Comple-
mentary Medicine (AMED), and PsycINFO, as well as studies obtained by handsearching of journals/abstracts. We also searched the follow-
ing trial registries: US National Institutes of Health Ongoing Trials Register, ClinicalTrials.gov, and the World Health Organization (WHO)
International Clinical Trials Registry Platform. We imposed no restriction on language of publication. We conducted our search in October
2017.
Selection criteria
We searched for randomised controlled trials comparing dual antibiotics versus a single antibiotic for short-term (< 4 weeks) or long-term
management of bronchiectasis diagnosed in adults and/or children by bronchography, plain film chest radiography, or high-resolution
computed tomography. Primary outcomes included exacerbations, length of hospitalisation, and serious adverse events. Secondary out-
comes were response rates, emergence of resistance to antibiotics, systemic markers of infection, sputum volume and purulence, mea-
sures of lung function, adverse events/effects, deaths, exercise capacity, and health-related quality of life. We did not apply outcome mea-
sures as selection criteria.
Data collection and analysis
Two review authors independently screened the titles and abstracts of 287 records, along with the full text of seven reports. Two studies
met review inclusion criteria. Two review authors independently extracted outcome data and assessed risk of bias. We extracted data from
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only one study and conducted GRADE assessments for the following outcomes: successful treatment of exacerbation; response rates; and
serious adverse events.
Main results
Two randomised trials assessed the effectiveness of oral plus inhaled dual therapy versus oral monotherapy in a total of 118 adults with
a mean age of 62.8 years. One multi-centre trial compared inhaled tobramycin plus oral ciprofloxacin versus ciprofloxacin alone, and one
single-centre trial compared nebulised gentamicin plus systemic antibiotics versus a systemic antibiotic alone. Published papers did not
report study funding sources.
Effect estimates from one small study with 53 adults showed no evidence of treatment benefit with oral plus inhaled dual therapy for the
following primary outcomes at the end of the study: successful management of exacerbation - cure at day 42 (odds ratio (OR) 0.66, 95%
confidence interval (CI) 0.22 to 2.01; 53 participants; one study; very low-quality evidence); number of participants with Pseudomonas
aeruginosa eradication at day 21 (OR 2.33, 95% CI 0.66 to 8.24; 53 participants; one study; very low-quality evidence); and serious adverse
events (OR 0.48, 95% CI 0.08 to 2.87; 53 participants; one study; very low-quality evidence). Similarly, researchers provided no evidence
of treatment benefit for the following secondary outcomes: clinical response rates - relapse at day 42 (OR 0.57, 95% CI 0.12 to 2.69; 53
participants; one study; very low-quality evidence); microbiological response rate at day 21 - eradicated (OR 2.40, 95% CI 0.67 to 8.65;
53 participants; one study; very low-quality evidence); and adverse events - incidence of wheeze (OR 5.75, 95% CI 1.55 to 21.33). Data
show no evidence of benefit in terms of sputum volume, lung function, or antibiotic resistance. Outcomes from a second small study with
65 adults, available only as an abstract, were not included in the quantitative data synthesis. The included studies did not report our
other primary outcomes: duration; frequency; and time to next exacerbation; nor our secondary outcomes: systemic markers of infection;
exercise capacity; and quality of life. We did not identify any trials that included children.
Authors' conclusions
A small number of studies in adults have generated high-quality evidence that is insufficient to inform robust conclusions, and studies in
children have provided no evidence. We identified only one dual-therapy combination of oral and inhaled antibiotics. Results from this
single trial of 53 adults that we were able to include in the quantitative synthesis showed no evidence of treatment benefit with oral plus
inhaled dual therapy in terms of successful treatment of exacerbations, serious adverse events, sputum volume, lung function, and an-
tibiotic resistance. Further high-quality research is required to determine the efficacy and safety of other combinations of dual antibiotics
for both adults and children with bronchiectasis, particularly in terms of antibiotic resistance.
P L A I N   L A N G U A G E   S U M M A R Y
Dual antibiotics for bronchiectasis
Background to the question
Bronchiectasis is a lung disease involving abnormal airways, leading to repeated chest infections, and associated with a mortality rate
more than twice that of the general population. Although previously considered a relatively rare disease, numbers appear to be increasing,
particularly for those over 75 years in low/middle-income countries. Antibiotics are the main therapy for chest infection, but their use must
be weighed against potential side effects and the risk of increasing resistance to antibiotic therapy. One strategy to improve response and/
or reduce antibiotic resistance involves giving two antibiotic agents at the same time: dual antibiotic therapy. This review therefore aimed
to evaluate the effects of dual antibiotics for treatment of adults and children with bronchiectasis.
Study characteristics
In October 2017, we identified two relevant studies comparing oral plus inhaled dual therapy versus oral therapy alone. They included a
total of 118 adults with an average age of 62.8 years. One study compared inhaled tobramycin plus oral ciprofloxacin with oral ciprofloxacin,
and the second study compared inhaled gentamicin plus a systemic (affecting the whole body, rather than just the lungs) antibiotic with
a systemic antibiotic alone. Only a research summary was available for the latter. Published papers did not report study funding sources
Main results
Results from one small trial of 53 adults show no evidence of treatment benefit with oral plus inhaled dual therapy in terms of success-
ful treatment of exacerbations, the occurrence of serious unwanted events, amount of phlegm, lung function, or resistance to antibiotic
treatment. However, we found insufficient evidence to permit confident conclusions about their use.
Quality of the evidence
The overall quality of the evidence was very poor, largely because one of the studies was not well described and included few participants.
Information on exacerbations, exercise ability, and quality of life was not reported. We did not identify any trials that compared other
types of dual antibiotic therapy, and we found none that included children. Therefore uncertainty remains concerning the use of dual
antibiotics, and further high-quality studies are needed to examine the role of dual antibiotics in the treatment of adults and children with
bronchiectasis.
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Summary of findings for the main comparison.   Oral + inhaled dual therapy compared with oral monotherapy for bronchiectasis
Oral + inhaled dual therapy compared with oral monotherapy for bronchiectasis
Patient or population: bronchiectasis
Setting: United Kingdom and United States
Intervention: oral + inhaled dual therapy
Comparison: oral monotherapy
Anticipated absolute effects* (95%
CI)
Outcomes
Risk
with oral
monothera-
py
Risk with oral + in-
haled dual thera-
py
Relative effect
(95% CI)
№ of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Successful treatment of exacer-
bation: number of participants
cured. Outcome assessed on day
42
444 per 1000 346 per 1000
(150 to 617)
OR 0.66
(0.22 to 2.01)
53
(1 RCT)
⊕⊝⊝⊝
Very lowa,b
 
Successful treatment of exacer-
bation: number of participants
with P aeruginosa eradication.
Outcome assessed on day 21
185 per 1000 346 per 1000
(130 to 652)
OR 2.33
(0.66 to 8.24)
53
(1 RCT)
⊕⊝⊝⊝
Very lowa,b
 
Serious adverse events. Outcome
assessed on day 42
148 per 1000 77 per 1000
(14 to 333)
OR 0.48
(0.08 to 2.87)
53
(1 RCT)
⊕⊝⊝⊝
Very lowa,b
 
Treatment response: relapse (day
42). Outcome assessed on day 42
185 per 1000 115 per 1000
(27 to 379)
OR 0.57
(0.12 to 2.69)
53
(1 RCT)
⊕⊝⊝⊝
Very lowa,b
 
Microbiological response: eradi-
cated. Outcome assessed on day
21
200 per 1000 375 per 1000
(143 to 684)
OR 2.40
(0.67 to 8.65)
49
(1 RCT)
⊕⊝⊝⊝
Very lowa,b
 
Hospitalisations     Not estimable (0 studies) -  
Death     Not estimable (0 studies) -  
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Quality of life     Not estimable (0 studies) -  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI)
CI: confidence interval; OR: odds ratio; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
aDowngraded one point for high risk of bias from incomplete outcome data
bDowngraded 2 points owing to imprecision (wide confidence intervals crossing the line of no effect and few events)
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B A C K G R O U N D
Description of the condition
Bronchiectasis not attributable to cystic fibrosis has been de-
scribed as non-CF bronchiectasis but, in accordance with cur-
rent clinical guidelines, we will referred to it as "bronchiectasis"
throughout this review (Polverino 2017). Bronchiectasis is a per-
sistent respiratory condition associated with progressive destruc-
tion of the airways due to a 'vicious cycle' of recurrent bacteri-
al infection, pulmonary inflammation, and consequent structur-
al damage (Cole 1997; Pasteur 2010). The pathological process of
bronchiectasis leads to disruption of the normal epithelial barri-
er, which consequently allows inhaled pathogens to both colonise
the airways and cause clinical episodes of infection (Cole 1986).
In severe cases, this cycle of infection may lead to repeated hos-
pitalisation, chronic respiratory failure, and death. An understand-
ing of the cycle is central to the management of bronchiectasis, as
strategies to arrest both inflammatory and bacterial components
are required to limit progression of lung injury. Approximately half
of presenting cases are idiopathic, but the most common cause is
a previous chest infection, such as bacterial pneumonia or tuber-
culosis (Pasteur 2010). Diagnosis is based on identification of one
or more abnormally dilated bronchi on high-resolution comput-
erised tomography (HRCT) with characteristic symptoms including
breathlessness, chronic productive cough, and recurrent lower res-
piratory tract infection (Chang 2010; Pasteur 2010; Polverino 2017).
Patients colonised with Pseudomonas aeruginosa and those with
a high annual exacerbation rate show accelerated decline in lung
function, reduced health-related quality of life (measured via St
George's Respiratory Questionnaire (SGRQ)), increased risk of hos-
pitalisation, and increased mortality risk (Evans 1996; Martinez Gar-
cia 2007; Wilson 1997). Low forced expiratory volume in one second
(FEV1) % predicted, a higher proportion of affected lobes, and in-
creased breathlessness are associated with increased risks of hos-
pitalisation and mortality (Chalmers 2014; Martinez Garcia 2014;
Seitz 2010).
Bacteria most commonly associated with infective exacerbations
include non-typeable Haemophilus influenzae, P aeruginosa, Strep-
tococcus pneumoniae, Staphylococcus aureus, and Moraxella ca-
tarrhalis (Foweraker 2011). The microbiological profile differs be-
tween adults and children, and Pseudomonas is more common
among adults. Pseudomonas is resistant to many oral antibiotics
and is very difficult to eradicate, but it is prevalent in only 0 to 6%
of children. Colonising pathogens such as Pseudomonas, H influen-
zae and M catarrhalis also commonly display antimicrobial resis-
tance as the result of frequent exposure to antimicrobial agents.
The main aims of therapeutic management include preservation
of lung function; reduction in symptoms, such as cough, breath-
lessness, and expectoration; reduction in the number and duration
of exacerbations; and improvement in quality of life (Lavery 2005;
Pasteur 2010).
Global prevalence estimates are confounded by variable diagnos-
tic strategies (Weycker 2005), as well as by higher prevalence rates
in developing countries (Habesoglu 2011), but the global burden
of bronchiectasis is increasing, with mortality rates rising by 3%
per year in England and Wales between 2001 and 2007 (Roberts
2010), and hospitalisations increasing by 3% per year in the Unit-
ed States over a nine-year period (Seitz 2010). Both Roberts 2010
and Seitz 2012 reported higher prevalence rates among women
and in people over 60 years of age. More recent studies suggest
that prevalence may be increasing more rapidly than was previ-
ously estimated. In Germany in 2013, prevalence was estimated
at 67 cases per 100,000 general population (Ringshausen 2015). In
the UK from 2004 to 2013, incidence rates rose by approximately
63%, with an increase from 21.2 to 35.2 in women, and from 18.2 to
26.9 in men, per 100,000 person-years (Quint 2016). Similarly, point
prevalence rose from 350.5 to 566.1 in women, and from 301.2 to
485.5 in men, per 100,000 head of population, with approximately
262,900 adults in the UK living with bronchiectasis in 2013. The dis-
ease has a significant impact on paediatric populations: Younger
children and those with more frequent exacerbations experience
worse quality of life (Kapur 2012a). Bronchiectasis is more com-
mon in some ethnic groups, for example, southwest Alaskan chil-
dren (16:1000) and Australian indigenous children (15:1000) (Chang
2002). Furthermore, one study reported an estimated incidence of
3.7 per 100,000 per year among children younger than 15 years of
age in New Zealand. This equates to a prevalence of 1:3000 children
overall and 1:625 in Pacific children (Twiss 2005). It also demon-
strates that the incidence rate among children in New Zealand is al-
most seven times higher than among those in Finland (Twiss 2005).
Average mortality rates per 100,000 general population in Europe
are estimated at 0.3 in 27 of the 28 EU countries (ranging from 0.01
in Germany to 1.18 in the UK) and at 0.2 in nine non-EU countries
(ranging from 0.01 in Azerbaijan to 0.67 in Kyrgyzstan), on the ba-
sis of 2005 to 2009 data (European Lung White Book 2013). More
recent UK estimates suggest that age-adjusted mortality rates are
2.26 times higher in women and 2.14 times higher in men compared
with the general population (Quint 2016).
Description of the intervention
The lungs of patients with bronchiectasis are commonly colonised
by bacteria, and treatment with antibiotics can help to decrease
bacterial load while reducing systemic inflammation (Kapur 2012).
Antibiotics are used to reduce bacterial burden and to tackle the
cycle of infection and lung damage, consequently helping to re-
duce the impact and frequency of chest infection and the frequency
and duration of hospital admissions, while also reducing mortali-
ty (Cole 1986; Pasteur 2010). Antibiotics can be administered on a
short-term (< 4 weeks) or longer-term (≥ 4 weeks) basis via various
modes, including oral, inhaled, and intravenous routes, with specif-
ic choice of antibiotic informed by analysis of sputum bacteriology.
Antibiotics serve as front-line therapy for management of bacterial
load, but their use is weighed against potential adverse effects and
increasing concerns about antibiotic resistance (Pasteur 2010).
'Combination' or 'dual' antibiotic therapy for bronchiectasis is de-
fined as the combination of two or more antibiotics, rather than as
use of a single antibiotic (monotherapy), irrespective of the route
of administration or the duration of therapy. Dual antibiotic ther-
apy is commonly administered therapeutically over a short dura-
tion (up to four weeks), rather than prophylactically for prevention,
and is commonly used to treat patients with acute exacerbations
whose lungs are colonised by multiple strains of bacteria with dif-
ferent patterns of antibiotic resistance, when monotherapy is un-
likely to be effective. Dual therapy may also be used when the clini-
cian is concerned about increasing the risk of antibiotic resistance,
for example, when antibiotics have been prescribed frequently or
for a prolonged duration. British Thoracic Society guidelines rec-
ommend the use of combination antibiotics when patients present
with multiple pathogens (Pasteur 2010).
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How the intervention might work
Chronic bacterial airway colonisation commonly occurs in pa-
tients with bronchiectasis; high bacterial load is associated with
increased inflammation and symptoms and worse quality of life
(McShane 2013). It has been hypothesised that inflammation con-
tributes to progression of bronchiectasis, and evidence suggests
that the presence of bacteria in the airways promotes inflammation
(Haworth 2014). Bronchiectatic airways are commonly colonised
by multiple bacteria or different strains of the same bacteria, some
of which may not be positively cultured in the laboratory. Bacte-
rial load can be reduced through treatment with systemic antibi-
otics (Rubin 2014), and various antibiotic strategies have been used
to reduce bacterial load and reinfection, including short-term (< 4
weeks) therapy for acute exacerbations and longer-term (≥ 4 weeks)
prophylactic therapy for frequent exacerbations characterised by
chronic sputum purulence (Chalmers 2012; Evans 2003). Although
longer-term antibiotics are not recommended for routine treat-
ment (Valery 2012; Wu 2014), they may be considered for treatment
of patients with frequent exacerbations (three or more per year re-
quiring antibiotic therapy) (Pasteur 2010). Dual antibiotic therapy
for exacerbations could reduce bacterial load and levels of inflam-
mation, consequently improving clinically meaningful outcomes,
such as length of exacerbation, frequency of exacerbation, disease
progression, and mortality.
Why it is important to do this review
The benefits and risks of dual antibiotics given for management
of acute exacerbations and for prophylaxis are currently unclear.
It is important to weigh the benefits of dual antibiotics in terms of
bacterial eradication and suppression of bacterial load against the
risks of enhanced antibiotic resistance and exposure to side effects
associated with multiple antibiotic therapy.
This review summarises available evidence on the use of dual an-
tibiotics for patients with bronchiectasis to inform clinical prac-
tice and future research needs. This review has been conducted
alongside two other, closely related reviews: Macrolide antibiotics
for bronchiectasis (Kelly 2018) andHead-to-head trials of antibiotics
for bronchiectasis (Kaehne 2017).
O B J E C T I V E S
To evaluate the effects of dual antibiotics in the treatment of adults
and children with bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) reported as full
text, those published as abstract only, and unpublished data.
Types of participants
We included adults and children with a clinical diagnosis of
bronchiectasis confirmed by plain film chest radiography or HRCT.
We excluded studies in which participants had received continuous
or high-dose antibiotics immediately before the study began or a
diagnosis of cystic fibrosis (CF), sarcoidosis, or active allergic bron-
chopulmonary aspergillosis.
Types of interventions
We included studies comparing dual antibiotics versus a single an-
tibiotic, provided that both arms included a common route of ad-
ministration. We planned to analyse short-course (< 4 weeks) and
long-term (≥ 4 weeks) dual antibiotics separately. This review fo-
cused on comparisons of antimicrobial agents and therefore ex-
cluded comparisons of macrolides owing to their anti-inflammato-
ry properties. Potential comparison groups for dual therapy versus
monotherapy included the following.
1. Oral dual therapy versus oral monotherapy.
2. Intravenous dual therapy versus intravenous monotherapy.
3. Oral + inhaled dual therapy versus oral monotherapy.
4. Oral + intravenous dual therapy versus oral monotherapy.
5. Inhaled + intravenous dual therapy versus inhaled monothera-
py.
6. Inhaled + oral dual therapy versus inhaled monotherapy.
7. Intravenous + inhaled dual therapy versus intravenous
monotherapy.
8. Intravenous + oral dual therapy versus inhaled monotherapy.
We included studies that compared one combination of antibiotics
versus another if a comparison was made between different classes
of antibiotics in combination (e.g. cephalosporin A + aminoglyco-
side A vs cephalosporin B + inhaled aminoglycoside B) or between
different administration routes for antibiotics from the same class
(e.g. IV cephalosporin + IV aminoglycoside vs IV cephalosporin + in-
haled aminoglycoside).
Types of outcome measures
Primary outcomes
1. Successful treatment of exacerbation
2. Length of exacerbation
3. Length of hospitalisation
4. Time to next exacerbation
5. Frequency of exacerbations
6. Serious adverse event - We used the definitions from Hansen
2015 to describe serious adverse events, which were those
that resulted in death or life-threatening events; requirement
for hospitalisation or prolongation of existing hospitalisation;
persistent or significant disability; or congenital anomalies, or
events that were considered medically important.
Secondary outcomes
1. Response rates as defined by study authors (e.g. diary cards of
physician global assessment)
2. Sputum volume and purulence
3. Measures of lung function (e.g. forced expiratory volume in one
second (FEV1))
4. Systemic markers of infection (e.g. leucocyte count, C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR))
5. Adverse events (e.g. cardiac arrhythmias, GI symptoms, hearing
impairment, nephrotoxicity)
6. Deaths
7. Emergence of resistance to antibiotics
8. Exercise capacity (e.g. Six-Minute Walk Distance (6MWD))
Dual antibiotics for bronchiectasis (Review)
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9. Quality of life (e.g. St George's Respiratory Questionnaire
(SGRQ))
10.Adverse/side effects
Reporting one or more of these outcomes was not a study inclusion
criterion for this review.
Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources.
1. Monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL), through the Cochrane Register of Studies On-
line (crso.cochrane.org).
2. Weekly searches of MEDLINE Ovid SP 1946 to date.
3. Weekly searches of Embase Ovid SP 1974 to date.
4. Monthly searches of PsycINFO Ovid SP 1967 to date.
5. Monthly searches of Cumulative Index to Nursing and Allied
Health Literature (CINAHL) EBSCO 1937 to date.
6. Monthly searches of Allied and Complementary Medicine
(AMED) EBSCO.
7. Handsearches of the proceedings of major respiratory confer-
ences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings, are provided in Appendix 1. See Appendix 2 for search
terms used to identify studies for inclusion in this review.
We will search the following trials registries.
1. US National Institutes of Health Ongoing Trials Register Clinical-
Trials.gov (www.clinicaltrials.gov).
2. World Health Organization International Clinical Trials Registry
Platform (apps.who.int/trialsearch).
We searched the Cochrane Airways Trials Register and additional
sources from inception to October 2017, with no restriction on lan-
guage of publication.
Searching other resources
We checked the reference lists of all primary studies and review ar-
ticles for additional references. We also searched for errata or re-
tractions from included studies published in full text on PubMed
(www.ncbi.nlm.nih.gov/pubmed) and reported the search date.
Data collection and analysis
Selection of studies
Two review authors (LF and SG) independently screened titles and
abstracts of all studies identified for inclusion as a result of the
search and coded them as 'retrieve' (eligible or potentially eligi-
ble/unclear) or 'do not retrieve.' The same two review authors inde-
pendently screened retrieved full-text study reports or publications
for inclusion and recorded reasons for exclusion of ineligible stud-
ies. They reported no disagreements with regard to study selection.
We recorded the study selection process using a PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses) flow
diagram and study details using Characteristics of excluded studies
tables (Moher 2009).
Data extraction and management
We used a data collection form, piloted on at least one study in the
review, to record study characteristics and outcome data. One re-
view author (RA) extracted the following study characteristics from
included studies.
1. Methods: study design, total duration of study, details of any
'run-in' period, number of study centres and locations, study
setting, withdrawals, dates of study.
2. Participants: N, mean age, age range, gender, severity of condi-
tion, diagnostic criteria, baseline lung function, smoking histo-
ry, inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant medica-
tions, excluded medications.
4. Outcomes: primary and secondary outcomes specified and col-
lected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial au-
thors.
Two review authors (DL and LF) independently extracted outcome
data from included studies and noted in the Characteristics of in-
cluded studies table when outcome data were not reported in a
useable way. We resolved disagreements by consensus or by con-
sultation with a third review author (SS or SJM). One review au-
thor (DL) transferred data into Review Manager (RevMan 2014). We
double-checked that data had been entered correctly by compar-
ing data presented in the systematic review with those provided in
the study reports. A second review author (RA) spot-checked study
characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (DL and LF) independently assessed the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions  (Higgins 2011).
We resolved disagreements by discussion with another review au-
thor (SS). We assessed risk of bias according to the following do-
mains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear
and provided a quote from the study report together with a jus-
tification for our judgement in the 'Risk of bias' table. We sum-
marised risk of bias judgements across different studies for each
of the domains listed. We considered blinding separately for differ-
ent key outcomes when necessary (e.g. for unblinded outcome as-
sessment, risk of bias for all-cause mortality may be very different
from risk of bias for a patient-reported pain scale). When informa-
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tion on risk of bias was related to unpublished data or correspon-
dence with a trialist, we noted this in the 'Risk of bias' table.
When considering treatment effects, we took into account risk of
bias for studies that contributed to those outcomes.
Assessment of bias in conducting the systematic review
We conducted the review according to the published protocol (Felix
2017).
Measures of treatment e9ect
We analysed dichotomous data as odds ratios, and continuous data
as mean differences or standardised mean differences. We entered
data presented as a scale with a consistent direction of effect.
We intended to undertake meta-analyses only when this was mean-
ingful (i.e. when treatments, participants, and the underlying clini-
cal question were similar enough for pooling to make sense). How-
ever, data were available from only one included study, and meta-
analysis was not possible. Nevertheless, we included the data nar-
ratively in the review.
We planned to narratively describe skewed data reported as medi-
ans and interquartile ranges.
If multiple arms had been reported in a single trial, we planned to
include only the relevant arms. Similarly, if two comparisons (e.g.
drug A vs placebo and drug B vs placebo) had been combined in
the same meta-analysis, we would have halved the control group
to avoid double-counting. None of the included studies included
more than two study arms.
Unit of analysis issues
In all included studies, the unit of analysis was the participant. In
terms of exacerbation rates and hospitalisation rates, we focused
on the number of events experienced by the participant during the
trial and analysed the results using rate ratios when possible.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data (e.g.
when a study was identified as abstract only). When this was not
possible, and the missing data were considered a serious source of
bias, we had planned to perform a sensitivity analysis to explore
the impact of including such studies in the overall assessment of
results.
One of the included studies was an abstract for which contact de-
tails for the principal investigator were not reported. We contacted
the institution to which the authors were affiliated to obtain more
information.
Assessment of heterogeneity
We planned to use the I2 statistic to measure heterogeneity among
studies in meta-analyses; in the presence of substantial hetero-
geneity, we would have explored possible causes by performing
prespecified subgroup analyses. As we conducted no meta-analy-
ses, we did not assess heterogeneity.
Assessment of reporting biases
Only two studies met the inclusion criteria; thus we identified fewer
than the recommended minimum number of eight studies required
to create a funnel plot to explore possible small-study and publica-
tion biases.
We were not able to pool the included studies and therefore were
unable to explore small-study and publication biases.
Data synthesis
We planned to use a random-effects model for meta-analyses and
to perform a sensitivity analysis using a fixed-effect model, but this
was not possible, as we were unable to pool data from the included
studies.
'Summary of findings' table
We created a 'Summary of findings' table using the following prima-
ry and secondary outcomes: exacerbations, hospitalisations, seri-
ous adverse events, response rates, deaths, and quality of life. We
used the five GRADE considerations (study limitations, consisten-
cy of effect, imprecision, indirectness, and publication bias) to as-
sess the quality of evidence related to included studies that con-
tributed data on our prespecified outcomes. We followed meth-
ods and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), and we used GRADEpro software (GRADEpro GDT).
We justified all decisions to downgrade or upgrade the quality of
studies by using footnotes and inserted comments to aid the read-
er's understanding of grades when necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Duration: short (< 4 weeks) or longer (≥ 4 weeks).
2. Type of antibiotic: aminoglycosides, beta-lactams, chloram-
phenicol, fluoroquinolones, macrolides, tetracyclines.
3. Children versus adults.
4. Pseudomonas colonisation versus no Pseudomonas colonisa-
tion.
We planned to use the following outcomes.
1. Exacerbations.
2. Hospitalisations.
3. Serious adverse events.
We planned to use the formal test for subgroup interactions provid-
ed in Review Manager (RevMan 2014).
However data available from the two included studies were insuf-
ficient to permit subgroup analyses.
Sensitivity analysis
We planned to evaluate the impact of methodological quality of in-
cluded studies using the following domains to remove studies at
high or unclear risk of bias: random sequence generation and allo-
cation concealment. Data were insufficient to undertake sensitivity
analyses.
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R E S U L T S
Description of studies
Results of the search
A systematic search, conducted in October 2017, identified 287
unique records of potentially relevant trials. Following inspection
of titles and abstracts, review authors considered 280 records as ir-
relevant. We obtained full texts for the remaining seven records and
included two studies that met review eligibility criteria (Bilton 2006;
Hossain 2010). See Characteristics of included studies. We exclud-
ed five records with reasons (documented in Excluded studies) and
summarised the selection process in the study flow diagram (Fig-
ure 1).
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Figure 1.   Study selection flow diagram.
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One included study originally aimed to test the use of nebulised
tobramycin to manage exacerbations of bronchiectasis (Bilton
2006). However, in keeping with recommendations of the research
ethics committee (communication with authors), investigators re-
designed the trial to test the effectiveness of tobramycin inhalation
plus oral ciprofloxacin compared with placebo inhalation plus oral
ciprofloxacin. We included the redesigned published study in this
review.
Included studies
Methods
Both of the included studies were RCTs (Bilton 2006; Hossain 2010).
Bilton 2006 was conducted in multiple centres across UK and USA,
and Hossain 2010 was conducted at a single centre in Bangladesh.
Ten participants withdrew from Bilton 2006 (five in the oral + in-
haled dual therapy (O + I) group, five in the oral monotherapy (O)
group).
Participants
The two studies included a total of 118 participants (Bilton 2006
= 53; Hossain 2010 = 65). Adults (72% female) aged 18 to 80 years
with a mean age of 62.8 years (± 11.5 years) participated in Bilton
2006. Bronchiectasis was confirmed by HRCT scan, and researchers
excluded from the study those with CF, allergic bronchopulmonary
aspergillosis, active tuberculosis, glucose-6-phosphate dehydroge-
nase deficiency, significant renal disease, or change in steroid ther-
apy within 2 weeks of the acute exacerbation. In addition, eligibili-
ty criteria included a history of chronic P aeruginosa, confirmed by
sputum culture, during the previous 12 months and at screening.
Furthermore, the P aeruginosa isolate had to demonstrate sensitiv-
ity to ciprofloxacin (minimum inhibitory concentration ≤ 4 µg/mL)
at study enrolment. The second study was reported as an abstract
alone and did not provide detailed information on participant char-
acteristics or study inclusion/exclusion criteria (Hossain 2010).
Smoking history
In Bilton 2006, one participant was a current smoker (place-
bo/oral ciprofloxacin group) and 20 participants (13 placebo/oral
ciprofloxacin; 7 tobramycin/oral ciprofloxacin) were former smok-
ers. Hossain 2010 did not report smoking history.
Interventions
Both studies assessed the effectiveness of oral plus inhaled dual
therapy versus oral monotherapy.
Bilton 2006 randomised participants to receive either tobramycin
inhalation solution (300 mg per 5 mL of inhalation solution) plus
oral ciprofloxacin (750 mg), or placebo (1.25 mg of quinine sulphate
per 5 mL of inhalation solution) plus oral ciprofloxacin (750 mg),
twice daily for 14 days.
Hossain 2010 randomised participants to receive either nebulised
gentamicin plus a systemic antibiotic or nebulised placebo plus a
systemic antibiotic. Study authors did not report information on
frequency and dose.
Outcomes
Primary outcomes
Successful treatment of exacerbation
Bilton 2006 reported this outcome as a cure rate using the following
definition:resolution or improvement of symptoms of acute exacer-
bation (day 21 - primary outcome).
Hossain 2010 reported this outcome using the following categori-
sation: resolved - resolution of symptoms and signs (S/S) of acute ex-
acerbation; improved - not fully resolved; not improved - no change
or deterioration of S/S.
Length of hospitalisation
Only Hossain 2010 reported this outcome.
Serious adverse events
Only Bilton 2006 reported this outcome. This study reported the
proportions of participants who required hospitalisation and treat-
ment for worsening symptoms such as dyspnoea, cough, chest
pain, or tightness that was associated with bronchiectasis and
chronic infection.
Length of exacerbation, time to next exacerbation, frequency of
exacerbations
The included studies did not report any of the above remaining pri-
mary outcomes.
Secondary outcomes
Response rates as defined by study authors (e.g. diary cards of
physician global assessment)
Bilton 2006 classified response as follows at day 21: failed - par-
ticipants with persistent or worsening symptoms of exacerbations,
hospitalisation, or administration of additional antibiotic; or inde-
terminate - participants with missing data and those without a de-
finitive cure or failure rate; or relapse (classified on day 42) - includ-
ing those who were cured on day 21 but required further treatment
with additional antibiotics.
Bilton 2006 also classified response rates according to microbio-
logical results at day 21. Researchers classified sputum culture as
"eradicated" (no P aeruginosa infection and/or inability to produce
sputum), "persistent" (with P aeruginosa infection and/or treat-
ment with additional antibiotics for continued infection), "superin-
fected" (new pathogen and new or worsening symptoms of infec-
tion), or "indeterminate" (unable to classify).
Sputum volume and purulence
Only Bilton 2006 reported sputum volume. Neither of the included
studies reported sputum purulence.
Measures of lung function (e.g. forced expiratory volume in one
second (FEV1))
Bilton 2006 measured FEV1 (L) at baseline and at 7 and 14 days. Hos-
sain 2010 also measured FEV1 (values not given) but did not report
the details.
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Serious adverse events (e.g. cardiac arrhythmias, GI symptoms,
hearing impairment, nephrotoxicity)
Both of the included studies reported serious adverse events (Bil-
ton 2006; Hossain 2010).
Deaths
Bilton 2006 and Hossain 2010 did not report this outcome mea-
sure, and it remains unclear whether any deaths occurred during
the study period. In Bilton 2006, 7 of 10 withdrawals were due to
adverse events, but study authors did not provide follow-up data,
so we do not know whether any deaths occurred in this group.
Emergence of resistance to antibiotics
Bilton 2006 reported emergence of P aeruginosa resistance to
ciprofloxacin and tobramycin.
Adverse/side e9ects
Bilton 2006 reported adverse effects of study medications.
Systemic markers of infection, exercise capacity, quality of life
Included studies did not report any of the above outcomes.
Notes
Neither of the included studies reported information on power cal-
culation to inform sample size, trial registration, funders, or the role
of sponsors. Trial authors did not provide conflict of interest state-
ments. Bilton 2006 reported that researchers obtained ethical ap-
proval for their trial.
Excluded studies
We recorded reasons for exclusion of five studies following exami-
nation of full text reports (see Characteristics of excluded studies).
Two studies did not meet study inclusion criteria for the interven-
tion, as the comparison arm was not given monotherapy (Orriols
1999; Orriols 2015). We excluded the remaining three studies be-
cause participants were not exclusively patients with bronchiecta-
sis and we were unable to contact trial authors to obtain informa-
tion on these participants alone (Takamoto 1994; Vergnon 1985;
Watanabe 1990).
Risk of bias in included studies
Two independent review authors (DL and LF) agreed on judge-
ments reported under the 'Risk of bias' section at the end of each
Characteristics of included studies table. Figure 2 and Figure 3 also
provide a summary of the risk of bias in both included studies.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
Allocation
We judged Bilton 2006 as having low risk of bias, as the randomisa-
tion sequence was computer generated. However, we judged Hos-
sain 2010 as having unclear risk because insufficient information
was provided in the abstract.
We judged Bilton 2006 as having low risk of bias for allocation
concealment following confirmation from trial authors that assign-
ment was concealed via an independent central allocation process.
We judged Hossain 2010 as having unclear risk owing to insufficient
information provided in the abstract.
Blinding
We judged Bilton 2006 as having low risk of bias for this domain.
The principal investigator confirmed that drugs were supplied by a
pharmaceutical company in identical opaque vials, and that both
drugs had a similar taste. We judged Hossain 2010 as having unclear
risk owing to insufficient information provided in the abstract.
We judged Bilton 2006 as having low risk of bias following confirma-
tion from the principal investigator that outcome assessors were
blinded to group allocation. We judged Hossain 2010 as having un-
clear risk owing to insufficient information provided in the abstract.
Incomplete outcome data
We judged Bilton 2006 as having high risk of attrition bias because
reasons for missing outcome data were not balanced between in-
tervention groups. We judged Hossain 2010 as having unclear risk
owing to insufficient information provided in the abstract.
Selective reporting
We classified risk of selective reporting bias as unclear for both of
the included studies because information on which to base a clear
judgement was insufficient (Bilton 2006; Hossain 2010).
Other potential sources of bias
We judged Bilton 2006 as having low risk of bias for this domain, as
no other sources of bias were identified. We judged Hossain 2010
as having unclear risk because information provided in the abstract
was insufficient.
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E9ects of interventions
See: Summary of findings for the main comparison Oral + inhaled
dual therapy compared with oral monotherapy for bronchiectasis
Primary outcomes
Successful treatment of exacerbation
Bilton 2006 reported no differences between groups in the number
of participants cured at day 21 (OR 0.42, 95% CI 0.14 to 1.30; one
study; 53 adults; Analysis 1.1) or at day 42 (OR 0.66, 95% CI 0.22 to
2.01; one study; 53 adults; Analysis 1.2). Researchers noted no dif-
ferences between groups in terms of number of participants with
P aeruginosa eradication at day 21 (OR 2.33, 95% CI 0.66 to 8.24;
Analysis 1.3). In Hossain 2010, participants receiving dual therapy
had an enhanced recovery rate compared with those receiving sys-
temic antibiotics alone at three time points (P = 0.05; P = 0.02; P =
0.02), but which of the four follow-up time points (day 3, 7, 14, or
21) is referred to remains unclear. The study report was available
only as an abstract and did not provide any quantitative data other
than the P value.
According to our GRADE assessment, we judged this outcome as
very low quality (Summary of findings for the main comparison).
Length of hospitalisation
Hossain 2010 reported that dual therapy reduced hospital stay
among participants in the intervention group; however, the ab-
stract did not include any quantitative data.
Serious adverse events
Bilton 2006 reported no differences between groups in frequency of
serious adverse events (OR 0.48, 95% CI 0.08 to 2.87; one study; 53
adults; Analysis 1.4). Four participants receiving monotherapy and
two receiving dual therapy required hospitalisation for worsening
symptoms such as dyspnoea, cough, and chest pain or tightness.
According to our GRADE assessment, we judged this outcome as
very low quality (Summary of findings for the main comparison).
Length of exacerbation, time to next exacerbation, frequency of
exacerbations
None of the included studies reported any of the above outcomes.
Secondary outcomes
Response rates
Response to treatment - failure or relapse
Treatment responses were not different between groups at day 21
for the classification of treatment failure (OR 2.75, 95% CI 0.79 to
9.62; one study; 53 adults; Analysis 1.5); nor at day 42 for the clas-
sifications of treatment relapse (OR 0.57, 95% CI 0.12 to 2.69; one
study; 53 adults; Analysis 1.6) and treatment failure (OR 2.75, 95% CI
0.79 to 9.62; one study; 53 adults; Analysis 1.7). Relapse rates were
not measured at day 21.
Microbiological response - eradicated, persistent, superinfected
Microbiological response was not different between groups at day
21 for the following classifications: eradicated (OR 2.40, 95% CI 0.67
to 8.65; Analysis 1.8); persistent (OR 0.37, 95% CI 0.11 to 1.26; Analy-
sis 1.9); and superinfected (OR 3.26, 95% CI 0.13 to 83.90; Analysis
1.10).
According to our GRADE assessment, we judged this outcome as
very low quality (Summary of findings for the main comparison).
Sputum volume and purulence
Bilton 2006 reported no statistically significant differences in mean
sputum volume at days 7 and 14 with dual therapy compared with
monotherapy.
Measures of lung function
Researchers noted no statistically significant differences in FEV1
between groups in the included studies. Bilton 2006 reported mean
FEV1 (L) graphically for all data collection points (days 7 and 14),
but it was not possible for review authors to accurately retrieve the
raw data. Hossain 2010 did not report further details.
Systemic markers of infection
None of the included studies reported this outcome.
Adverse events
Researchers noted no differences between groups in the number
of people who experienced an adverse event in Bilton 2006 (OR
0.21, 95% CI 0.02 to 2.03; Analysis 1.11). However, the incidence
of wheeze was significantly higher in the dual therapy group com-
pared with the monotherapy group (OR 5.75, 95% CI 1.55 to 21.33;
Analysis 1.12). Data show no differences between groups in terms
of adverse events arising from the use of study medications, al-
though it is unclear from the paper whether this relates specifically
to the antibiotic interventions (OR 1.45, 95% CI 0.49 to 4.31; Analy-
sis 1.13). Hossain 2010 reported that five participants in the dual
therapy group developed wheeze and chest tightness following ad-
ministration of nebulised gentamicin. It remains unclear whether
any of the participants in the monotherapy group experienced an
adverse event.
Deaths
Neither of the included studies explicitly reported any deaths,
Emergence of resistance to antibiotics
Data show no differences between groups in the development
of antibiotic resistance in Bilton 2006. One patient receiving
dual tobramycin+ciprofloxacin therapy entered the study with to-
bramycin-susceptible P aeruginosa strains that became resistant
by the end of the study. No participants receiving ciprofloxacin
monotherapy developed tobramycin-resistantP aeruginosa strains
during the study.
Exercise capacity
Neither Bilton 2006 nor Hossain 2010 reported this outcome.
Quality of life
Neither of the two included studies reported this outcome.
D I S C U S S I O N
Summary of main results
Two randomised trials met the inclusion criteria for this systemat-
ic review (Bilton 2006; Hossain 2010); both assessed the effective-
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ness of oral plus inhaled dual therapy versus oral monotherapy,
and both were conducted in adults. Bilton 2006 was a multi-centre
trial conducted in UK and USA, and Hossain 2010 was a single-cen-
tre study conducted in Bangladesh. Only an abstract was available
for Hossain 2010, and outcomes were described narratively or re-
sults were reported as the P value alone; therefore we were unable
to include these data in the quantitative data synthesis.
We found no evidence of treatment effect with oral plus inhaled
dual therapy for all outcomes reported in the summary of findings,
including successful treatment of exacerbations, serious adverse
events, and response rates, although the effect estimate was based
on one small study of 53 adults (Bilton 2006). Similarly, we found
no evidence of effect on sputum volume, lung function, adverse
events, or antibiotic resistance.
Overall completeness and applicability of evidence
Of the pre-defined potential comparison groups, we identified on-
ly one group (oral plus inhaled dual therapy vs oral monotherapy)
for inclusion in the review. The comparison included only two small
studies with a total of 118 participants. Our search did not identi-
fy any other comparisons that met our study selection criteria. The
two included studies did not report some of our primary outcomes
(length, frequency, and time to next exacerbation) and did not re-
port some of our secondary outcomes (systemic markers of infec-
tion, exercise capacity, and quality of life). It is particularly impor-
tant to measure the impact of this chronic condition on health-re-
lated quality of life from the patient's perspective. Furthermore, we
were unable to obtain quantitative data for pooled analyses or to
adequately assess risk of bias for one study, as findings were avail-
able only in a conference abstract. We did not identify any stud-
ies that evaluated the use of dual antibiotics in children, or that
assessed long-term (more than four weeks) use of dual antibiotic
therapy; we identified insufficient studies to permit assessment of
effects by class of antibiotic. Similarly, we found insufficient stud-
ies to conduct sensitivity analyses. Our findings therefore are limit-
ed by scant available data, and we were unable to evaluate all out-
comes planned in the protocol.
Quality of the evidence
We judged overall quality of the evidence as very low for outcomes
included in the GRADE assessment. Only one comparison - oral plus
inhaled dual antibiotic versus oral antibiotic alone - was assessed,
and included studies did not report several of the outcomes that we
planned to include in our GRADE assessment. We judged the qual-
ity of evidence as very low for the three outcomes included in the
GRADE assessment (treatment of exacerbations, response rate, and
serious adverse events). All outcomes were limited by incomplete
outcome data. We considered effects as imprecise owing to wide
confidence intervals that crossed the line of no effect and inclusion
of few events and small sample sizes.
Potential biases in the review process
We used a comprehensive systematic search, conducted by a highly
experienced information specialist, to identify potentially eligible
studies. We also searched multiple resources including electronic
databases, journals, conference proceedings, reference lists of in-
cluded studies, citations of included studies, and trial registries.
Nevertheless, we recognise the possibility of publication bias in this
review, which could lead to overestimation or underestimation of
effects of the intervention in terms of the different outcomes in-
cluded in this review. Trials showing no, or negative, effects are less
likely to be offered for publication, and, if offered, they are less like-
ly to be accepted, resulting in a biased set of data available for re-
view. We were able to extract quantitative data from only one study
and were unable to assess the presence of publication bias through
formal testing.
Furthermore, some papers may have been misclassified as not el-
igible for inclusion in the review. However, two review authors in-
dependently assessed all studies, and a third review author verified
selection, so we are confident that we assessed studies excluded
from the analyses on the basis of consistent and appropriate crite-
ria. We double-checked all data to avoid extraction and transcrip-
tion errors.
We contacted the investigators of both included studies to request
further information on trial methods and outcome data. The author
of one trial, published as a full-text paper, provided clarification on
randomisation procedures. We did not receive a response from the
authors of the study that was published only as an abstract. We al-
so contacted the author of one excluded study published in a non-
English language but did not receive a response. We obtained trans-
lations of two non-English language studies that we excluded fol-
lowing inspection of the translated text. We were unable to conduct
planned subgroup or sensitivity analyses owing to the small num-
ber of included studies.
Agreements and disagreements with other studies or
reviews
There are no previous versions of this review. We included in this
review two small trials that assessed the effectiveness of oral plus
inhaled dual therapy versus oral monotherapy alone, with a total of
118 adult participants and no children. We highlighted the pauci-
ty of evidence in this area in relation to all important outcomes
and, in accordance with this lack of evidence, identified no pub-
lished reviews of the relevant benefits and risks of combined an-
tibiotics compared with monotherapy in bronchiectasis. A review
of single versus combination intravenous antibiotics for eradicat-
ing Pseudomonas aeruginosa in people with cystic fibrosis found
no significant benefit associated with a beta-lactam or aminoglyco-
side monotherapy compared with a beta-lactam-aminoglycoside
combination upon examination of poor quality evidence (Elphick
2005). However, recent bronchiectasis guidelines emphasise differ-
ences in treatment responses between bronchiectasis and cystic fi-
brosis, and although the guidelines provide no specific recommen-
dations for dual therapy, they do offer recommendations for use
of antibiotics in people with this condition (Polverino 2017). This
review cannot inform robust recommendations for practice owing
to insufficient high-quality evidence, and review authors found no
evidence related to the role of dual antibiotics in the treatment of
children.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This systematic review identified minimal published evidence to
guide clinical practice on the routine use of dual antibiotics for
treatment of patients with bronchiectasis.
Only two published trials with 118 adult participants met our
inclusion criteria; these studies evaluated the addition of neb-
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ulised aminoglycosides to systemic antibiotics. Bilton and col-
leagues investigated the addition of nebulised tobramycin to
oral ciprofloxacin for treatment of 53 adult patients with acute
Pseudomonas aeruginosa infection in bronchiectasis. Researchers
found no evidence of treatment benefit with oral plus inhaled dual
therapy in terms of successful treatment of exacerbations, serious
adverse events, sputum volume, lung function, and antibiotic resis-
tance. Hossain reported the results of a single-centre placebo-con-
trolled comparison of systemic antimicrobials versus the addition
of nebulised gentamicin, but we were unable to include this study
in the quantitative synthesis. Both studies reported a higher inci-
dence of wheeze with dual therapy. Overall, we have very low con-
fidence in the outcomes presented.
Review authors have identified the need for better quality evidence
on the benefits and risks of dual antibiotics to guide clinical practice
in the treatment of patients with bronchiectasis.
Implications for research
Our review highlights the need for additional long-term ran-
domised placebo-controlled trials to determine the effectiveness
of dual antibiotics versus single antibiotics for treatment of adults
and children with bronchiectasis. The two included studies com-
pared oral plus inhaled dual therapy versus oral therapy alone, but
no trials have compared other combinations of modes of adminis-
tration (e.g. intravenous and inhaled; different antibiotics delivered
via a common mode of administration, such as two inhaled antibi-
otics). Some evidence from observational studies of dual antibiot-
ic regimens suggests that including nebulised antibiotics is more
effective than providing intravenous regimens alone for eradicat-
ing Pseudomonas aeruginosa. (Orriols 1999), This and other com-
parisons require formal testing in randomised controlled trials to
establish the relative benefits of different types of dual therapy.
The overall quality of evidence derived from the two included stud-
ies is very poor, and we found no data on our primary outcomes
of duration, frequency, or time to next exacerbation, nor on our
secondary outcomes of microbiological infection measures, exer-
cise capacity, and quality of life. Furthermore neither of the includ-
ed trials enrolled children or investigated long-term (more than
four weeks) use of dual antibiotic therapy. Future high-quality stud-
ies should consider both short- and long-term antibiotic manage-
ment for adults and children including our prespecified review out-
comes, especially health-related quality of life, and should report
data on adults and children separately. We also consider it impor-
tant to assess the relative risks and benefits of continuous ver-
sus cyclical antibiotic administration, but this question will be ad-
dressed in a separate review.
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Characteristics of included studies [ordered by study ID]
 
Methods Aims: to test the effect of adding tobramycin inhaled solution to oral ciprofloxacin for the treatment of
acute exacerbations of non-cystic fibrosis bronchiectasis in patients with P aeruginosa infection
Design: a double-blind, randomised, active comparator, parallel-design study
Total study duration: 42 days from randomisation, not including the 28-day pre-screening run-in pe-
riod. Elapsed time between pre-screening and randomisation differed for each participant as partici-
pants were randomised during an exacerbation
Number of study centres and locations: multiple (17 centres): 5 in the United Kingdom, 12 in the Unit-
ed States
Study setting: home (participants received the first dose of study drug on day 1 in the presence of
study personnel but took subsequent doses at home)
Methods of recruitment: unclear
Study start and end dates: not reported
Withdrawals: 10 participants withdrew from the study (5 from inhaled tobramycin + oral ciprofloxacin
group, 5 from oral ciprofloxacin group). Seven withdrawals (2 from inhaled tobramycin + oral
ciprofloxacin group and 5 from oral ciprofloxacin group) were due to adverse events. Among these, 3
participants (1 from inhaled tobramycin + oral ciprofloxacin group, and 2 from oral ciprofloxacin group)
withdrew owing to possibly drug-related adverse events, and 4 in the oral ciprofloxacin group with-
drew on day 21 or later owing to non-drug-related adverse events. Three participants in the inhaled
tobramycin + oral ciprofloxacin group withdrew from the study owing to "unsatisfactory therapy re-
sponses" after receiving 8, 8, and 15 days of dosing, respectively. One participant from the inhaled to-
bramycin + oral ciprofloxacin group who withdrew at day 8 owing to "unsatisfactory therapeutic re-
sponses" also had an adverse event.
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Analysis by intent to treat: yes. It was reported that "safety and efficacy analysis was performed on
the study population, which included all randomised participants who had received at least one dose
of study medication."
Participants 53 adults were randomised
Inclusion criteria: history of chronic P aeruginosa lung infection, confirmed by a sputum culture that
was positive for P aeruginosa both within 12 months before screening and at the time of screening. In
addition, P aeruginosa had to show ciprofloxacin sensitivity (mic < 4) at the time of study enrolment.
Participants who did not experience an acute exacerbation within 2 months of the screening visit were
rescreened for study eligibility
Exclusion criteria: cystic fibrosis, allergic bronchopulmonary aspergillosis, active tuberculosis, glu-
cose-6-phosphate dehydrogenase deficiency, significant renal disease, change in steroid therapy with-
in 2 weeks of exacerbation
Mean age: inhaled tobramycin + oral ciprofloxacin: 61.4 years; placebo/ciprofloxacin: 63.7 years
Age range: 18 to 80 years
Gender: inhaled tobramycin + oral ciprofloxacin group: 20 women, 6 men; placebo/ciprofloxacin
group: 18 women, 9 men
Diagnostic criteria: men and women between 18 and 80 years of age with bronchiectasis confirmed by
central reading of an HRCT scan
Severity of condition: not stated
Baseline lung function: placebo/ciprofloxacin group: FEV1 51.4% predicted, FVC 70.4% predicted. In-
haled tobramycin + oral ciprofloxacin group: FEV1 53.2% predicted, FVC 70% predicted
Smoking history: placebo/ciprofloxacin group: current smokers 0, former smokers 10. Inhaled to-
bramycin + oral ciprofloxacin group: current smokers 1, former smokers 7
Baseline imbalances: No significant imbalances were identified. 13% of ciprofloxacin-resistant partici-
pants were excluded from the study
Interventions Inhaled tobramycin + oral ciprofloxacin group (n = 26)
Ciprofloxacin
Dose: 750 mg
Delivery mode: oral
Frequency: twice daily
Duration: 14 days
Tobramycin inhaled solution
Dose: 300 mg per 5 mL
Delivery mode: aerosolised with the use of a jet nebuliser
Frequency: twice daily
Duration: 14 days
Ciprofloxacin + placebo group (n = 27)
Ciprofloxacin
Dose: 750 mg
Bilton 2006  (Continued)
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Delivery mode: oral
Frequency: twice daily
Duration: 14 days
Placebo
Dose: 1.25 mg quinine sulphate per 5 mL
Delivery mode: aerosolised with the use of a jet nebuliser
Frequency: twice daily
Duration: 14 days
Adherence: Study personnel were present during administration of the first dose on day 1
Run-in phase: 28 days
Run-out phase: none
Participants were not allowed to use inhaled tobramycin within 28 days before screening or between
screening and exacerbation event. Maintenance therapy with antibiotics, including aerosolised antibi-
otics other than inhaled tobramycin, was allowed up until the time of exacerbation; no changes were
permitted within 14 days before the exacerbation and during the study period
Outcomes Participants kept a structured respiratory symptoms diary
Primary
Clinical efficacy: assessed on days 14, 21, and 42, and classified as follows.
Day 14
• Resolved (all signs and symptoms returned to pre-exacerbation state)• Improved (but condition had not fully resolved or there were residual symptoms)• Not improved (no change or condition has worsened)
Day 21
• Cured (resolution or improvement in symptoms of acute exacerbation)• Failed (persistence or worsening of symptoms of exacerbation, hospitalisation, or administration of
additional antimicrobial therapy)• Indeterminate (participants with missing data or without a clear cure or fail response)
Day 42
• Cured• Failed• Indeterminate• Relapsed (cured on day 21, but subsequently requiring treatment with additional antibiotics)
Sputum microbiology was classified on day 21 as follows, based on sputum culture findings.
• Eradicated (no P aeruginosa infection/unable to produce sputum)• Persistent (P aeruginosa infection and/or treated with additional antibiotics for continued infection)• Superinfected (new pathogen and new or worsening symptoms of infection)• Indeterminate (did not fit in to any of the above categories)
Secondary
Pulmonary function tests: FEV1 (L) assessed on days 0, 7, and 14
Bilton 2006  (Continued)
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Adverse event rate
Post hoc analysis: concordance of clinical and microbiological outcomes at day 21, which included
clinical efficacy (cured) and P aeruginosa eradication
Notes Power calculation: not reported
Trial registration: not reported
Conflicts of interest: not reported
Funders: not reported
Role of the sponsors: not reported
Ethical approval: achieved at each participating centre
Conclusions:
"The addition of an inhaled tobramycin solution to therapy with oral ciprofloxacin for the treatment of
acute exacerbations of bronchiectasis due to P aeruginosa improved microbiological outcome and was
concordant with clinical outcome; the inability to demonstrate an additional clinical benefit may have
been due to emergent wheeze resulting from treatment"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote (from correspondence): "randomisation was computer generated with
sites telephoning the company's central number in order to allocate the spe-
cific numbered vials"
Allocation concealment
(selection bias)
Low risk Correspondence with the principal investigator of the study confirmed that
random sequence was allocated centrally
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote (from correspondence): "patients and the research team were blinded
as the placebo was supplied by the company who made TOBI (by then I think it
was Novartis) and the placebo contained something to make it taste the same
as TOBI"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote (from correspondence): "assessment of endpoints was also blind as
none of the patients filling in symptom questionnaires and none of the lab
staG working on the microbiology knew which treatment a patient was on"
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Of 5 participants in the inhaled tobramycin + oral ciprofloxacin group who
withdrew from the study, 2 withdrew owing to drug-related adverse events
and 3 because of an "unsatisfactory therapeutic response" after receiving at
least 8 days of study drug. In the oral ciprofloxacin group, only 1 participant
withdrew owing to drug-related adverse events and the remaining 4 with-
drawals were attributed to non-drug-related adverse events
Comment: Reasons for missing outcome data were imbalanced between the 2
groups and may have been related to the intervention
Selective reporting (re-
porting bias)
Unclear risk Insufficient information available to permit a judgement of 'low risk' or 'high
risk.' Trial authors acknowledge that important outcomes such as time-to-
next-exacerbation and time-to-next- exacerbation-requiring-hospitalisation
were not assessed in this study
Other bias Low risk The study appears to be free of other sources of bias
Bilton 2006  (Continued)
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Methods Aims: to investigate the efficacy of adding nebulised gentamicin to systemic antibiotics to improve
clinical outcomes during an exacerbation of bronchiectasis. The clinical outcome was categorised as
follows: resolved, improved but not fully resolved, or not improved
Design: randomised controlled trial
Total study duration: 21 days
Number of study centres and locations: single; Dhaka, Bangladesh
Study setting: National Institute of Diseases of the Chest
Methods of recruitment: unclear
Study start and end dates: not reported
Analysis by intent to treat: not stated
Withdrawals: 11 in total, 3 from the nebulised gentamicin + systemic antibiotic group and 8 from the
placebo + systemic antibiotic group. Withdrawals were due to failure to attend follow-up clinic
Exact withdrawals are unclear owing to inconsistent reporting in the abstract: nebulised gentamicin +
systemic antibiotic group started with 35 participants, with 3 withdrawals leaving 32, but the abstract
states that 30 participants completed the study in the nebulised gentamicin + systemic antibiotic group
Participants 65 adults were randomised
Settings: National Institute of Diseases of the Chest
Country: Bangladesh
Inclusion criteria: diagnosis of bronchiectasis deemed to be exacerbating and treated with systemic
antibiotics
Exclusion criteria: not reported
Methods of recruitment: not reported
Mean age: not reported
Age range: not reported
Gender: not reported
Diagnostic criteria: not reported
Severity of condition: not reported
Baseline lung function : not reported
Smoking history : not reported
Baseline imbalances: not reported
Interventions Nebulised gentamicin + systemic antibiotic group (n = 35)
Dose: not stated
Placebo + systemic antibiotic group (n = 30)
Dose: not stated
Adherence: not reported
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Run-in phase: not reported
Run-out phase: not reported
Outcomes Primary: exacerbation status classified at days 3, 7, 14, and 21 as follows.
• Resolved – resolution of S/S of acute exacerbation• Improved – not fully resolved• Not improved – if no change or deterioration in S/S
Secondary: not reported
Post hoc analysis: not reported
Notes Power calculation: not reported
Trial registration: unclear
Conflicts of interest: not reported
Funders: not reported
Role of the sponsors: not reported
Ethical approval: not reported
Conclusions:
"(1) Addition of nebulized gentamicin to systemic antibiotic improves clinical efficacy compared to on-
ly systemic antibiotic. (2) It can reduce hospital stay when used as adjuvant with systemic antibiotic for
the treatment of exacerbation of bronchiectasis"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Details of the randomisation process were not reported
Allocation concealment
(selection bias)
Unclear risk Details of the allocation process were not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk The study was not described as blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The assessment was not described as blinded. The outcome assessment in-
cluded severity of exacerbation, but it is not clear how this was assessed or by
whom
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 3 from intervention group and 8 from placebo group did not attend follow-up
visits, but no further details are reported
Selective reporting (re-
porting bias)
Unclear risk Only data reported in an abstract were available
Other bias Unclear risk The abstract did not report baseline values, so the potential for baseline im-
balances was unclear. Similarly, no data were provided on route of administra-
tion of systemic antibiotics nor on adherence
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FEV1: forced expiratory volume in one second; FVC: forced vital capacity; HRCT: high-resolution computed tomography; MIC: minimum
inhibitory concentration; TOBI:Tobramycin
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Orriols 1999 Did not meet inclusion criteria for the intervention. Nebulised dual antibiotic vs symptomatic treat-
ment (i.e. comparison arm was not given a monotherapy antibiotic)
Orriols 2015 Did not meet inclusion criteria for the intervention. The study compared nebulised dual antibiotics
with symptomatic treatment (i.e. comparison arm was not given a monotherapy antibiotic)
Takamoto 1994 The intervention was not exclusively restricted to participants with bronchiectasis, and it is unclear
whether the study was randomised. We were unable to contact trial authors for clarification on
study design or data on participants with bronchiectasis alone
Vergnon 1985 The intervention was not exclusively restricted to participants with bronchiectasis, and we were
unable to contact trial authors for data on these participants alone
Watanabe 1990 The intervention was not exclusively restricted to participants with bronchiectasis, and it is unclear
whether the study was randomised. We were unable to contact trial authors for clarification on
study design or data on participants with bronchiectasis alone
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Oral + inhaled dual therapy versus oral monotherapy
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Successful treatment of ex-
acerbation: cured (day 21)
1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Successful treatment of ex-
acerbation: cured (day 42)
1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Pseudomonas eradication 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Serious adverse events 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Treatment failure (day 21) 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Treatment relapse (day 42) 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Treatment failure (day 42) 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Microbiological response:
eradicated
1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Microbiological response:
persistent
1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
10 Microbiological response:
superinfected
1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
11 Adverse events (any) 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
12 Adverse events: wheeze 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
13 Adverse events related to
study medications
1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 1.1.   Comparison 1 Oral + inhaled dual therapy versus oral
monotherapy, Outcome 1 Successful treatment of exacerbation: cured (day 21).
Study or subgroup Dual therapy Monothrapy Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 13/26 19/27 0.42[0.14,1.3]
Favours monotherapy 1000.01 100.1 1 Favours dual therapy
 
 
Analysis 1.2.   Comparison 1 Oral + inhaled dual therapy versus oral
monotherapy, Outcome 2 Successful treatment of exacerbation: cured (day 42).
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 9/26 12/27 0.66[0.22,2.01]
Favours monotherapy 1000.01 100.1 1 Favours dual therapy
 
 
Analysis 1.3.   Comparison 1 Oral + inhaled dual therapy versus
oral monotherapy, Outcome 3 Pseudomonas eradication.
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 9/26 5/27 2.33[0.66,8.24]
Favours monotherapy 1000.01 100.1 1 Favours dual therapy
 
 
Analysis 1.4.   Comparison 1 Oral + inhaled dual therapy
versus oral monotherapy, Outcome 4 Serious adverse events.
Study or subgroup Dual Mono Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 2/26 4/27 0.48[0.08,2.87]
Favours dual therapy 1000.01 100.1 1 Favours monotherapy
Dual antibiotics for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
26
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
 
Analysis 1.5.   Comparison 1 Oral + inhaled dual therapy versus
oral monotherapy, Outcome 5 Treatment failure (day 21).
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 10/26 5/27 2.75[0.79,9.62]
Favours dual therapy 1000.01 100.1 1 Favours monotherapy
 
 
Analysis 1.6.   Comparison 1 Oral + inhaled dual therapy versus
oral monotherapy, Outcome 6 Treatment relapse (day 42).
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 3/26 5/27 0.57[0.12,2.69]
Favours dual therapy 1000.01 100.1 1 Favours monotherapy
 
 
Analysis 1.7.   Comparison 1 Oral + inhaled dual therapy versus
oral monotherapy, Outcome 7 Treatment failure (day 42).
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 10/26 5/27 2.75[0.79,9.62]
Favours dual therapy 1000.01 100.1 1 Favours monotherapy
 
 
Analysis 1.8.   Comparison 1 Oral + inhaled dual therapy versus oral
monotherapy, Outcome 8 Microbiological response: eradicated.
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 9/24 5/25 2.4[0.67,8.65]
Favours monotherapy 1000.01 100.1 1 Favours dual therapy
 
 
Analysis 1.9.   Comparison 1 Oral + inhaled dual therapy versus oral
monotherapy, Outcome 9 Microbiological response: persistent.
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 13/24 19/25 0.37[0.11,1.26]
Favours dual therapy 1000.01 100.1 1 Favours monotherapy
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Analysis 1.10.   Comparison 1 Oral + inhaled dual therapy versus oral
monotherapy, Outcome 10 Microbiological response: superinfected.
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 1/24 0/25 3.26[0.13,83.9]
Favours dual therapy 1000.01 100.1 1 Favours monotherapy
 
 
Analysis 1.11.   Comparison 1 Oral + inhaled dual therapy
versus oral monotherapy, Outcome 11 Adverse events (any).
Study or subgroup Dual Mono plus placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 22/26 26/27 0.21[0.02,2.03]
Favours dual therapy 1000.01 100.1 1 Favours monotherapy
 
 
Analysis 1.12.   Comparison 1 Oral + inhaled dual therapy
versus oral monotherapy, Outcome 12 Adverse events: wheeze.
Study or subgroup Dual therapy Monotherapy Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 13/26 4/27 5.75[1.55,21.33]
Favours dual therapy 1000.01 100.1 1 Favours monotherapy
 
 
Analysis 1.13.   Comparison 1 Oral + inhaled dual therapy versus oral
monotherapy, Outcome 13 Adverse events related to study medications.
Study or subgroup Dual therapy Monotherapy Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Bilton 2006 13/26 11/27 1.45[0.49,4.31]
Favours dual therapy 1000.01 100.1 1 Favours monotherapy
 
 
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register (CAGR)
Electronic searches: core databases
 
Database Frequency of search
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
  (Continued)
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CENTRAL (the Cochrane Library) Monthly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
  (Continued)
 
Handsearches: core respiratory conference abstracts
 
Conference Years searched
American Academy of Allergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International Primary Care Respiratory Group Congress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
  (Continued)
 
MEDLINE search strategy used to identify trials for the CAGR
Bronchiectasis search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify RCTs
1. exp "clinical trial [publication type]"/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
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6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and the RCT filter (Lefebvre 2011) were adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Anti-Bacterial Agents Explode 1
#6 antibiotic* or anti-biotic*
#7 anti-bacteri* or antibacteri*
#8 *cillin
#9 *mycin or micin*
#10 *oxacin
#11 *tetracycline
#12 macrolide*
#13 quinolone*
#14 trimethoprim
#15 ceph*
#16 sulpha*
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #4 and #17
[In search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, bronchiectasis]
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External sources• The review authors declare that no such funding was received for this systematic review, UK.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We have noted no differences between the review and the planned protocol, although we found insufficient evidence to conduct all pre-
planned analyses.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents  [*therapeutic use];  Bronchiectasis  [*drug therapy]  [microbiology];  Ciprofloxacin  [*therapeutic use];  Gentamicins
  [*therapeutic use];   Pseudomonas Infections   [*drug therapy];   Pseudomonas aeruginosa;   Randomized Controlled Trials as Topic;
  Tobramycin  [*therapeutic use]
MeSH check words
Adult; Humans; Middle Aged
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